Search
Nov 5
BIO-Europe: Galimedix is developing amyloid beta aggregation modulators to try to block toxic Aβ upstream of where most others have focused - the lead programs are in ophthalmology
Executive Chairman Alexander Gebauer describes this approach to aiming to prevent toxic amyloid beta clumps from developing in the first...